Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1/2 2Phase 4 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Lymphoma 35Lymphoma, Follicular 31Lymphoma, Non-Hodgkin 30Leukemia, Lymphocytic, Chronic, B-Cell 16Recurrence 11Lymphoma, Large B-Cell, Diffuse 11Leukemia 11Lymphoma, B-Cell 10Waldenstrom Macroglobulinemia 8Lymphoma, T-Cell, Cutaneous 8Hodgkin Disease 8Mycosis Fungoides 6Lymphoma, Mantle-Cell 6Neoplasm, Residual 5Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Lymphoma, Extranodal NK-T-Cell 5Febrile Neutropenia 5Burkitt Lymphoma 5Asthma 5Pain 4Neoplasms 4Multiple Myeloma 4Lymphoma, Large-Cell, Anaplastic 4Leukemia, Myeloid, Acute 4Hematologic Diseases 4Sezary Syndrome 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3

Interventions

rasburicase 1Urate Oxidase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Tumor Lysis Syndrome × Lymphoid × Clear all
NCT00230217 2009-03-30

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Sanofi

Phase 4 Completed
94 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms, Recurrence, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡